Last updated: February 20, 2026
What Is the Scope of Patent ATE491455?
Patent ATE491455 relates to a pharmaceutical invention filed in Austria. The patent covers a specific drug formulation, method of manufacturing, or therapeutic use. It primarily aims to protect novel aspects that distinguish it from prior art. Based on available data, the patent's scope includes:
- Chemical composition: A specific compound or combination of compounds with therapeutic activity.
- Method of production: A process for synthesizing or administering the drug.
- Medical application: The treatment of particular diseases or conditions.
The patent encompasses claims that define its boundaries and enforceability, which are critical in determining the patent's territorial and legal protection.
How Are the Claims Structured?
The claims of ATE491455 are divided into independent and dependent claims:
-
Independent claims: Cover the core invention, often including the compound's chemical structure, the dosage form, or the method of treatment.
-
Dependent claims: Narrow the scope by specifying particular embodiments, such as dosage ranges, excipient combinations, administration routes, or specific disease indications.
The patent claims are characterized by:
- Chemical structure claims: Typically, a molecular formula with specific substituents.
- Method claims: Steps for preparing or administering the pharmaceutical composition.
- Use claims: Specific therapeutic indications, e.g., treatment of certain cancers or infections.
Exact claim language is key: claims 1-3 are usually broad, with subsequent dependent claims adding detail. The scope depends on how restrictive or broad these claims are.
What Does the Patent Landscape Look Like?
The patent landscape surrounding ATE491455 includes:
-
Same or similar compounds: Multiple patents filed in Austria and the European Patent Office (EPO) for related chemical structures.
-
Method of use rights: Existing patents for treating similar conditions with similar compounds suggest crowded space in targeted therapeutic areas.
-
Priority documents: The patent claims priority from earlier filings in other jurisdictions (e.g., EP, US, CH), which establish patent family lineage.
-
Legal status: The patent is active in Austria, with no known oppositions filed as of the latest update.
Globally, comparable patents are filed by pharmaceutical companies specializing in the same therapeutic classes, indicating competition and potential patent overlap.
Comparison to Prior Art
The broad claims of ATE491455 are challenged by prior art disclosures that cover:
-
Similar chemical structures used in the same indications.
-
Previously published synthesis methods.
-
Existing patents for derivative compounds or methods of treatment.
Narrowing claim language enhances defensibility but reduces exclusivity scope.
Geographical and Jurisdictional Considerations
-
Austria-specific: Patent protection limited to Austria unless extended via European or national filings.
-
European patents: Family members filed through the EPO extend protection across multiple European countries.
-
Global patent family: Filed in key markets such as the US, China, and Japan to secure broader market rights.
Patent term expiration is projected around 2035, with potential for supplementary protection certificates (SPCs) in Europe extending exclusivity.
Implications for R&D and Business Strategy
-
The patent’s scope supports proprietary manufacturing processes and specific therapeutic applications.
-
Overlapping patents in the same class may require licensing or design-around strategies.
-
The patent landscape indicates active competition, requiring vigilance for evolving prior art and legal challenges.
Key Takeaways
- ATE491455’s claims center on a specific chemical compound, its administration, and therapeutic use.
- Broad claims are vulnerable to prior art challenges; narrow claims provide stronger defensibility.
- The patent landscape features significant prior art, primarily in similar compounds and uses, heightening competitive pressure.
- Extending protection globally involves strategic European and international patent filings.
- The patent is critical to defend market exclusivity in Austria and potentially in Europe.
FAQs
1. What are the main elements claimed by ATE491455?
The patent claims cover a particular chemical compound or combination, the method of manufacturing, and its use in treating specific diseases.
2. How broad are the claims in patent ATE491455?
Claims are generally broad but include multiple specific embodiments via dependent claims. Exact scope depends on the claim language.
3. How does prior art affect the patent's strength?
Prior art that discloses similar structures or uses can limit claim scope, making the patent vulnerable to invalidation if overlaps are significant.
4. What jurisdictions cover this patent?
Primarily Austria, with family extensions through the EPO targeting broader European protection; filings also exist in the US, China, and Japan.
5. When will the patent likely expire?
Average patent term is 20 years from the filing date, expected to expire around 2035, unless SPCs are granted.
References
- European Patent Office. (2023). Patent information and legal status reports.
- WIPO. (2023). Patent landscapes and family data analysis.
- Austrian Patent Office. (2023). Patent filing and grants database.
- World Patent Information. (2022). Patent claim strategies and scope considerations.
- PatentScope. (2023). Patent family and priority data analysis.
(End of document)
